BBIO
USDBridgeBio Pharma Inc. Common Stock
Reaalajas hind
Hinnagraafik
Põhinäitajad
Turunäitajad
Avatud
$61.420
Kõrge
$61.905
Madal
$60.230
Maht
2.10M
Ettevõtte fundamentaalnäitajad
Turukapitalisatsioon
11.8B
Tööstusharu
Biotehnoloogia
Riik
United States
Kauplemisstatistika
Keskmine maht
2.63M
Börs
NMS
Valuuta
USD
52 nädala vahemik
Seotud uudised
BridgeBio to Participate in November Investor Conferences
PALO ALTO, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a new type of biopharmaceutical company focused on genetic diseases, today announced that
BridgeBio to Present Data from the Overall ATTR-CM Variant and V142I (V122I) Populations from ATTRibute-CM at the AHA Scientific Sessions 2025
PALO ALTO, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a new type of biopharmaceutical company focused on genetic diseases, announced today that ten
HC Wainwright & Co. Reiterates Buy on BridgeBio Pharma, Maintains $90 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates BridgeBio Pharma with a Buy and maintains $90 price target.
Goldman Sachs Maintains Buy on BridgeBio Pharma, Raises Price Target to $100
Goldman Sachs analyst Paul Choi maintains BridgeBio Pharma with a Buy and raises the price target from $55 to $100.
TD Cowen Maintains Buy on BridgeBio Pharma, Raises Price Target to $95
TD Cowen analyst Tyler Van Buren maintains BridgeBio Pharma with a Buy and raises the price target from $60 to $95.
Raymond James Reiterates Outperform on BridgeBio Pharma, Raises Price Target to $71
Raymond James analyst Martin Auster reiterates BridgeBio Pharma with a Outperform and raises the price target from $69 to $71.
Cantor Fitzgerald Maintains Overweight on BridgeBio Pharma, Raises Price Target to $110
Cantor Fitzgerald analyst Josh Schimmer maintains BridgeBio Pharma with a Overweight and raises the price target from $100 to $110.
Seotud aktsiad
Püsi kursis
Määrake hinnateavitused, hankige tehisintellekti analüüsi uuendusi ja reaalajas turuuudiseid.